Navigation Links
Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Date:9/11/2012

Palmin, President and CEO of Novelos.  "We believe the data generated from the ongoing HOT Phase 1b trial combined with cancerous tumor imaging data from the ongoing I-124-CLR1404 (LIGHT) clinical trials will enable selection of indications for HOT Phase 2 trials and guide trial designs."

About HOT
HOT is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that we believe has first-in-class potential.  HOT is comprised of a proprietary phospholipid ether analog (PLE), acting as a cancer-targeted delivery and retention vehicle, covalently labeled with iodine-131, a cytotoxic (cell-killing) radioisotope that is already in common use to treat thyroid and other cancer types.  The ongoing Phase 1b dose-escalation trial is aimed at determining the Maximum Tolerated Dose of HOT.  We expect to initiate HOT Phase 2 efficacy trials as a monotherapy for solid tumors with significant unmet medical need as soon as a starting dose is established, subject to additional funding.  We may determine such a dose based on an efficacy signal or an acceptable safety profile in the Phase 1b trial.  Selection of indications for Phase 2, as well as aspects of trial design, will be guided by ongoing PET imaging trials in cancer patients with I-124-CLR1404 (LIGHT), a chemically identical biomarker for HOT.  Preclinical experiments in more than a dozen in vivo (in animals) tumor models have demonstrated selective killing of cancer cells along with a benign safety profile.  In view of HOT's selective uptake and retention in a wide range of solid tumors and in cancer stem cells, its single-agent efficacy in animal models and its non-specific mechanism of cancer-killing (radiation), we are first developing HOT as a monotherapy for solid tumors with significant unmet medical need.

About Novelos Therapeutics, Inc.
We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of can
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
11. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 3SBio Inc. (NASDAQ: ... China -based biotechnology company focused ... announced today that, at an extraordinary general meeting ... in favor of the proposal to authorize and ... merger dated February 8, 2013, among Decade Sunshine ...
(Date:5/23/2013)... PARÍS, 24 de mayo de 2013  Volcano ... desarrollador y fabricante de herramientas de precisión para ... tratamiento de la enfermedad vascular periférica y coronaria, ... ( Ad enosine V asodilator I ... durante la sesión de ensayo clínico hot line ...
(Date:5/23/2013)... -- Amgen (NASDAQ: AMGN ) will present at ... Thursday, May 30, 2013, at the Westin Boston Waterfront Hotel, ... Daylight Time. Arvind Sood , vice president ... Live audio of the presentation can be accessed from the ... A replay of the webcast will also be available on ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... ULURU Inc. (NYSE AMEX: ... development of a portfolio of wound management and oral ... for investment commitments with Ironridge Global BioPharma and its ... transactions, subject to certain conditions, to purchase common and ...
... Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), ... Data Safety Monitoring Board (DSMB) recently completed a ... Soligenix,s confirmatory Phase 3 clinical trial of orBec® ... acute gastrointestinal Graft-versus-Host disease (GI GVHD). ...
Cached Medicine Technology:ULURU Inc. Enters Into Strategic Financings of Up to $1.6 Million at a Premium to Current Share Price 2ULURU Inc. Enters Into Strategic Financings of Up to $1.6 Million at a Premium to Current Share Price 3Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 2Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 3Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 4Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 5Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 6
(Date:5/25/2013)... Dr. Leslie Gerstman announced today that ... skin on the neck, on the brow and under the ... , Ultherapy is a non-surgical procedure for the face and ... lift the skin over time. The use of FDA-cleared ultrasound ... then treat the deepest support layers of the skin – ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 Actos ... underway in U.S. District Court, Western District of Louisiana, ... According to a Case Management Order issued on May ... filing of contested motions in the Actos bladder cancer ... (In re: Actos Product Liability Litigation, MDL No. 2299) ...
(Date:5/25/2013)... Studies from Johns Hopkins University reveal a ... and their inability to get adequate sleep. These same ... naturally relieve many symptoms. , Johns Hopkins University ... was significantly associated with overall weight loss, especially belly ... November 6th, 2012, researchers monitored 77 participants who were ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 The ... ranging from irritable bowel syndrome (IBS) to bloating, ... among the most long-lasting, embarrassing, frustrating and difficult ... foods for digestive health have provided a ... are many factors contributing to digestive health issues, ...
(Date:5/25/2013)... 2013 Dr. Farooq Ashraf, founder of ... Dubai, has announced his practice’s adoption of The iFS ... FDA-cleared femtosecond laser proven with more than 10 years ... of LASIK. , “We are happy to announce that ... at our Dubai LASIK practice,” Ashraf said Thursday. “We ...
Breaking Medicine News(10 mins):Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2
... Oyster-related infections up, while Salmonella plateaus, says CDC report ... report a continuing decline in food-related illnesses caused by several ... , But Vibrio , a pathogen most often acquired ... is on the rise, while rates of Salmonella infection have ...
... says back disorders in the working population are among ... world. Disc degeneration is the main suspected origin of ... surgery. But Videman, a researcher in the University of ... common perception that disc degeneration is caused by physical ...
... Low levels of vitamin D are associated with lower lung ... to researchers at National Jewish Health. In a paper published ... Clinical Immunology, Daniel Searing, MD, and his colleagues also ... most effective controller medication for asthma. , "Asthmatic children in ...
... ... that Maureen Hanrahan has joined the company as a senior consultant specializing in managed ... SCHIP. , ... April 15, 2010 -- ArpegioHealth is pleased to announce that Maureen Hanrahan ...
... ... Workers’ Compensation claim for the amount of $34,000.00. , ... New Bedford, MA (PRWEB) April, 15, 2010 -- The law firm of Dussault and ... , ,The employee was injured while on the job while working as a truck-cleaner. The ...
... management of related condition leaves many undiagnosed, , THURSDAY, ... often fail to detect cases of chlamydia in young ... researchers contend. , They say that many urologists are ... known as epididymo-orchitis, which causes inflammation of the testicle ...
Cached Medicine News:Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 2Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 3Health News:Low vitamin D levels associated with more asthma symptoms and medication use 2Health News:Hanrahan Joins ArpegioHealth Consulting Firm 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: